Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Review

Research Support, Non-U.S. Gov't

Meta-Analysis

Multicenter Study

Systematic Review

Randomized Controlled Trial

Clinical Trial, Phase I

Clinical Trial, Phase III

Observational Study

Comparative Study

Case Reports

Historical Article

Network Meta-Analysis

Editorial

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Tyrosine Kinase Inhibitors""[mesh_terms]

30 Results

Searching titles within these results

Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management.

Hang Zhang, Kenneth K W To

Clinical and translational science 2024;17(11):e70053

Free Full Text

Abstract

Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors.

Rocio I R Macias, Jose J G Marin, Maria A Serrano, Sofia Del Carmen, Oscar Briz, Meraris Soto, Ruba Al-Abdulla, Elisa Herraez, Dominik Bettinger, Heike Bantel, Andreas Geier

Biochemical pharmacology 2023;217():115812

Free Full Text

Abstract

A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?

Shengyou Lin, Jiang Yan, Menglei Wang, Jialin Zhang, Jinhua Lu, Jingyang Su

Current opinion in oncology 2023;35(2):132-144

Full Text

Abstract

Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test.

L Agate, R Elisei, E Molinaro, E Minaldi, B Pontillo-Contillo, A Matrone, C Giani, L Valerio

Journal of endocrinological investigation 2023;46(8):1663-1671

Free Full Text

Abstract

Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.

Yuping Xie, Jiayi Yu, Xingchen Peng, Zheran Liu, Yonglin Su

Clinical endocrinology 2024;100(4):379-388

Full Text

Abstract

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.

Céleste Lebbe, David Combarel, Léa Dousset, Pauline Tetu, Angelo Paci, Nicolas Meyer, Stéphane Bouchet, Joseph Ciccolini, Florent Ferrer

Critical reviews in oncology/hematology 2024;200():104385

Full Text

Abstract

Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants.

Xiaoran Zhang, Gexin Shi, Shaorong Li, Jing Rao, Qing Wen, Hengli Zhao

Clinical pharmacology in drug development 2023;12(6):639-644

Full Text

Abstract

A review on tyrosine kinase inhibitors for targeted breast cancer therapy.

Balu Alagar Venmathi Maran, Poornima Sivamani, Conrad Ondieki Miruka, Byeong-Cheol Ahn, Prakash Gangadaran, Rajapandiyan Krishnamoorthy, Ramya Lakshmi Rajendran, Vidya Sankarapandian

Pathology, research and practice 2024;263():155607

Full Text

Abstract

Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.

Ruiyuan Jiang, Guang Lin, Huanping Zhang, Kena Sun, Xiaojia Wang

Cancer control : journal of the Moffitt Cancer Center 2024;31():10732748241278039

Free Full Text

Abstract

Drug-like properties of tyrosine kinase inhibitors in ophthalmology: Formulation and topical availability.

Einar Stefánsson, Thorsteinn Loftsson, Phatsawee Jansook

International journal of pharmaceutics 2024;655():124018

Full Text

Abstract

Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance.

Sofia Trocchianesi, Agnese Po, Elisabetta Ferretti, Giuseppina Catanzaro, Cosimo Durante, Rossella Elisei, Antonella Verrienti, Valeria Pecce, Tanja Milena Autilio, Zein Mersini Besharat, Aurelia Rughetti, Zaira Spinello, Anna Citarella

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023;164():114995

Free Full Text

Abstract

Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.

Jia Deng, Jian Gao, Ziyue Liao

Current oncology (Toronto, Ont.) 2023;30(1):1243-1254

Free Full Text

Abstract

Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review.

Lisa Prior, Michael E Kelly, Ian Brennan, Alison Corr, Niall J O'Sullivan, Hugo C Temperley, Tatiana S Temperley

Irish journal of medical science 2024;193(3):1143-1147

Full Text

Abstract

Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell Carcinoma.

Melek Karakurt Erylmaz, Mustafa Korkmaz

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2023;33(6):653-658

Full Text

Abstract

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors.

Shijun Wang, Shanshan Su, Zhibo Gai, Magdalena Rausch, Fangrui Xiu, Michele Visentin

International journal of molecular sciences 2023;24(3):2101

Free Full Text

Abstract

Results: 1 – 15 / 30

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Tyrosine Kinase Inhibitors""[mesh_terms]

Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management.

Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors.

A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?

Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test.

Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.

Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants.

A review on tyrosine kinase inhibitors for targeted breast cancer therapy.

Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.

Drug-like properties of tyrosine kinase inhibitors in ophthalmology: Formulation and topical availability.

Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance.

Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.

Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review.

Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line Treatment of Metastatic Renal Cell Carcinoma.

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors.

Results for
""Tyrosine Kinase Inhibitors""[mesh_terms]